Summit Therapeutics's price surge today seems to be confirming the bullish analyst outlook on the stock. Ending the day at $7.84, SMMT has posted 3.8% gains, pushing the valuation of the stock even higher. Might the stock be overvalued, despite its buy rating?
The first step in determining whether a stock is overvalued is to check its price to book (P/B) ratio. This is perhaps the most basic measure of a company's valuation, which is its market value divided by its book value. Book value refers to the sum of all of the company's assets minus its liabilities -- you can also think of it as the company's equity value.
Traditionally, value investors would look for companies with a ratio of less than 1 (meaning that the market value was smaller than the company's book value), but such opportunities are very rare these days. So we tend to look for company's whose valuations are less than their sector and market average. The P/B ratio for Summit Therapeutics is 124.44, compared to its sector average of 3.61 and the S&P 500's average P/B of 4.59.
Modernly, the most common metric for valuing a company is its Price to Earnings (P/E) ratio. It's simply today's stock price of 7.84 divided by either its trailing or forward earnings, which for Summit Therapeutics are $0.38 and $-0.29 respectively. Based on these values, the company's trailing P/E ratio is 20.6 and its forward P/E ratio is -27.0. By way of comparison, the average P/E ratio of the Health Care sector is 27.53 and the average P/E ratio of the S&P 500 is 27.65.
Indebted or mismanaged companies can't sustain shareholder value for long, even if they have strong earnings. For this reason, considering Summit Therapeutics's ability to meet its debt obligations is also an important aspect of pinning down its valuation. By adding up its current assets, then subtracting its inventory and prepaid expenses, and then dividing the whole by its current liabilities, we obtain the company's Quick Ratio of 6.725. Since SMMT's quick ratio is higher than 1, its total liquid assets are sufficient to meets its current liabilities.
Lastly, we consider Summit Therapeutics's free cash flow of $-76888000. This is the sum of all of its incoming and outgoing cash flows -- including those that are unrelated to its core business, such as rent, legal costs, income from investments, debt payments, etc. A negative cash flow for a single quarter is not a particularly serious issue for a company that does not pay a dividend. But if the cash flows are negative or erratic over several years, the company may be in trouble.
Shares of Summit Therapeutics appear to be overvalued at today's prices — despite the positive outlook from analysts. But sometimes stocks with inflated valuations turn out to be strong performances for years, and even decades, such as Amazon. So be sure to do your own due diligence if you are interested in taking a long position in SMMT.
